Other Systemic Treatments for Breast Cancer

  • Mário Alberto D. L. da Costa
  • Rodrigo Moura de Araújo


With the advent of information on molecular biology, receptors and cell signaling pathways and new agents are being developed and the expectation of improved results is great.

Recommended Reading

The studies listed below are recent reviews about the medicaments mentioned in this chapter.

  1. 1.
    Finn RS, Martin M, Rugo HS, et al. Palbociclib and letrozole in advanced breast cancer. N Engl J Med. 2016;375:1925–36.CrossRefGoogle Scholar
  2. 2.
    Guerrero-Zotano A, Mayer IA, Arteaga CL. PI3K/AKT/mTOR: role in breast cancer progression, drug resistance, and treatment. Cancer Metastasis Rev. 2016;35:515–24.CrossRefGoogle Scholar
  3. 3.
    Loibl S, Gianni L. HER2-positive breast cancer. Lancet. 2017;389:2415–29.CrossRefGoogle Scholar
  4. 4.
    McArthur HL, Page DB. Immunotherapy for the treatment of breast cancer: checkpoint blockade, cancer vaccines, and future directions in combination immunotherapy. Clin Adv Hematol Oncol. 2016;14:922–33.PubMedGoogle Scholar
  5. 5.
    Robson M, Im S, Senkus E, et al. Olaparib for metastatic breast cancer in patients with a germline BRCA mutation. N Engl J Med. 2017;377:523–33. Scholar

Copyright information

© Springer Nature Switzerland AG 2019

Authors and Affiliations

  • Mário Alberto D. L. da Costa
    • 1
  • Rodrigo Moura de Araújo
    • 2
  1. 1.Clinical OncologyOncoclínicas do BrasilRio de JaneiroBrazil
  2. 2.Clinical OncologyNational Cancer InstituteRio de JaneiroBrazil

Personalised recommendations